
Novartis grabs kidney drug developer Regulus in $1.7bn deal
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a total value of up to $1.7 billion. Shares in the San …